AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$ENGN

Grossman William purchased $10K of ENGN

Grossman William (Interim Chief Medical Officer) purchased 5,102 shares of enGene Therapeutics Inc. (ENGN) at $1.97 on 2026-09-22.

Original reporting
SEC EDGAR · Grossman William
Published Sep 24, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ENGN
Bullish
medium confidence
Mentioned
$ENGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENGNBullishLow
01

Why it matters

The insider buy adds a modest positive signal but is unlikely to move the stock significantly.

02

Market read

A routine insider purchase with minimal material impact; useful for tracking insider activity but not a strong trade catalyst.

03

What to watch

Potential upcoming clinical data releases could be the real driver of future price moves.

Relevance 4/10Novelty 5/10Timing: post‑market 2026‑09‑22

Background

Form 4 filings disclose insider trades; small purchases are common and often have limited market impact.

Company-level read

Ticker impact

$ENGNBullishMedium confidence
Context

Interim CMO Grossman William purchased 5,102 shares of ENGN for $10,050 in an open‑market transaction.

Expected impact

Potential slight upside pressure, but limited due to low transaction size.

Evidence & confidence

The purchase is under $20k and represents a tiny fraction of float, so market impact is likely minimal.

Market effects

Sector

Minor signal for biotech sector; no broad implications.

Regional

Limited to US biotech investors.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

The purchase may be routine compensation rather than a strong endorsement of the company's prospects.

Key entities

  • Company
    enGene Therapeutics Inc.

    Biotech firm developing gene‑editing therapies, ticker ENGN.

  • Insider
    Grossman William

    Interim Chief Medical Officer of ENGN.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ENGN insider trading history →

Related articles

SEP 8
$ENGNMed

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics reported Q3 2026 financial results, with $266.3M in cash and a net loss of $32.5M. The company plans to update key regulatory data, hold a pre-BLA meeting, and initiate a BLA submission for detalimogene in Q4 2026. It also announced a surfactant safety run-in clearance and a webinar on preclinical data. The company is well-capitalized to support BLA filing and precommercial readiness.

leaderpost.com3 min
SEP 8
$ENGNMedAI 9/10

enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary

enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.

tradingview.com1 min
SEP 8
$ENGNMed

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Bio

SEC EDGAR 8-K2 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 15
$ENGNMed

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Ap

SEC EDGAR 8-K6 min